{"nctId":"NCT00356915","briefTitle":"Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.","startDateStruct":{"date":"2006-07"},"conditions":["Onychomycosis"],"count":1381,"armGroups":[{"label":"Itraconazole tablets","type":"EXPERIMENTAL","interventionNames":["Drug: Itraconazole 200mg tablets"]},{"label":"Itraconazole capsules","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Itraconazole 100mg capsules"]},{"label":"Placebo tablets","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo tablets"]}],"interventions":[{"name":"Itraconazole 100mg capsules","otherNames":["Sporanox®"]},{"name":"Itraconazole 200mg tablets","otherNames":["Onmel"]},{"name":"Placebo tablets","otherNames":["placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of onychomycosis of at least one great toenail\n* Percent Nail Involvement Score of the more severely affected great toenail (the Target Toenail) must be between 2 and 3 (25-75% of the nail unit).\n* Length of Unaffected Part of the Target Toenail ≥2mm\n* Direct microscopic examination with KOH that is positive for the hyphae associated with dermatophytes on the target toenail\n* Subjects must have signed informed consent\n* If the subject is woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control until the first menses after 60 days following the last dose of study medication.\n\nExclusion Criteria:\n\n* Onychomycosis caused by Candida spp. without the presence of a dermatophyte\n* Participation in a clinical trial for the systemic treatment of onychomycosis of the toenail within 24 weeks prior to Visit 1\n* Use of systemic antifungals within 12 weeks prior to Visit 1\n* Use of topical antifungal nail lacquer within 30 days prior to Visit 1\n* Use of any other topical onychomycosis treatment on any toenail within 7 days prior to Visit 1\n* Evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF\n* Known liver disease or a history of liver toxicity with other drugs\n* Use of systemic immunosuppressants","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical and Mycological Cure of Target Toenail","description":"This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets.\n\nClinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules","description":"The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator's Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"21.7","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement of the Target Toenail","description":"Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52.\n\nThe Investigator's Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement.\n\n0 = Clinical Cure: No evidence of onychomycosis.\n\n1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \\>50% dystrophy with onycholysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"29.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement Compared to Placebo","description":"Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52.\n\nThe Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement.\n\n0 = Clinical Cure: No evidence of onychomycosis.\n\n1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \\>50% dystrophy with onycholysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":582},"commonTop":["Hypoacusis"]}}}